Created at	Source	Raw Value	Validated value
Dec. 30, 2021, 4:30 a.m.	usa	Safety of the SARS-CoV-2 protein subunit recombinant vaccine within 7 days after each dose	Safety of the SARS-CoV-2 protein subunit recombinant vaccine within 7 days after each dose
Oct. 6, 2021, 11:30 a.m.	usa	Phase II Immunogenicity profile of the SARS-CoV-2 protein subunit recombinant vaccine after whole schedule dose;Phase I Safety of the SARS-CoV-2 protein subunit recombinant vaccine within 7 days after each dose	Phase II Immunogenicity profile of the SARS-CoV-2 protein subunit recombinant vaccine after whole schedule dose;Phase I Safety of the SARS-CoV-2 protein subunit recombinant vaccine within 7 days after each dose